



THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

FTO genotype is associated with phenotypic variability of body mass index

Citation for published version:

Yang, J, Loos, RJF, Powell, JE, Medland, SE, Speliotes, EK, Chasman, DI, Rose, LM, Thorleifsson, G, Steinthorsdottir, V, Mägi, R, Waite, L, Smith, AV, Yerges-Armstrong, LM, Monda, KL, Hadley, D, Mahajan, A, Li, G, Kapur, K, Vitart, V, Huffman, JE, Wang, SR, Palmer, C, Esko, T, Fischer, K, Zhao, JH, Demirkan, A, Isaacs, A, Feitosa, MF, Luan, J, Heard-Costa, NL, White, C, Jackson, AU, Preuss, M, Ziegler, A, Eriksson, J, Kutalik, Z, Frau, F, Nolte, IM, Van Vliet-Ostaptchouk, JV, Hottenga, J-J, Jacobs, KB, Verweij, N, Goel, A, Medina-Gomez, C, Estrada, K, Bragg-Gresham, JL, Sanna, S, Sidore, C, Tyrer, J, Teumer, A, Prokopenko, I, Mangino, M, Lindgren, CM, Assimes, TL, Shuldiner, AR, Hui, J, Beilby, JP, McArdle, WL, Hall, P, Haritunians, T, Zgaga, L, Kolcic, I, Polasek, O, Zemunik, T, Oostra, BA, Junttila, MJ, Grönberg, H, Schreiber, S, Peters, A, Hicks, AA, Stephens, J, Foad, NS, Laitinen, J, Pouta, A, Kaakinen, M, Willemssen, G, Vink, JM, Wild, SH, Navis, G, Asselbergs, FW, Homuth, G, John, U, Iribarren, C, Harris, T, Launer, L, Gudnason, V, O'Connell, JR, Boerwinkle, E, Cadby, G, Palmer, LJ, James, AL, Musk, AW, Ingelsson, E, Psaty, BM, Beckmann, JS, Waeber, G, Vollenweider, P, Hayward, C, Wright, AF, Rudan, I, Groop, LC, Metspalu, A, Khaw, KT, van Duijn, CM, Borecki, IB, Province, MA, Wareham, NJ, Tardif, J-C, Huikuri, HV, Cupples, LA, Atwood, LD, Fox, CS, Boehnke, M, Collins, FS, Mohlke, KL, Erdmann, J, Schunkert, H, Hengstenberg, C, Stark, K, Lorentzon, M, Ohlsson, C, Cusi, D, Staessen, JA, Van der Klauw, MM, Pramstaller, PP, Kathiresan, S, Jolley, JD, Ripatti, S, Jarvelin, M-R, de Geus, EJC, Boomsma, DI, Penninx, B, Wilson, JF, Campbell, H, Chanock, SJ, van der Harst, P, Hamsten, A, Watkins, H, Hofman, A, Witteman, JC, Zillikens, MC, Uitterlinden, AG, Rivadeneira, F, Zillikens, MC, Kiemeny, LA, Vermeulen, SH, Abecasis, GR, Schlessinger, D, Schipf, S, Stumvoll, M, Tönjes, A, Spector, TD, North, KE, Lettre, G, McCarthy, MI, Berndt, SI, Heath, AC, Madden, PAF, Nyholt, DR, Montgomery, GW, Martin, NG, McKnight, B, Strachan, DP, Hill, WG, Snieder, H, Ridker, PM, Thorsteinsdottir, U, Stefansson, K, Frayling, TM, Hirschhorn, JN, Goddard, ME & Visscher, PM 2012, 'FTO genotype is associated with phenotypic variability of body mass index', *Nature*, vol. 490, no. 7419, pp. 267-272. <https://doi.org/10.1038/nature11401>

Digital Object Identifier (DOI):

[10.1038/nature11401](https://doi.org/10.1038/nature11401)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Nature

Publisher Rights Statement:

NIH Public Access Author manuscript. Europe PubMed open access link

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.



Published in final edited form as:

Nature. 2012 October 11; 490(7419): 267–272. doi:10.1038/nature11401.

***FTO* genotype is associated with phenotypic variability of body mass index**

Jian Yang^{1,2}, Ruth J. F. Loos^{3,4}, Joseph E. Powell^{1,2}, Sarah E. Medland², Elizabeth K. Speliotes^{5,6}, Daniel I. Chasman^{7,8}, Lynda M. Rose⁷, Gudmar Thorleifsson⁹, Valgerdur Steinthorsdottir⁹, Reedik Mägi^{10,11}, Lindsay Waite¹², Albert Vernon Smith^{13,14}, Laura M. Yerges-Armstrong¹⁵, Keri L. Monda¹⁶, David Hadley¹⁷, Anubha Mahajan¹¹, Guo Li¹⁸, Karen Kapur^{19,20}, Veronique Vitart²¹, Jennifer E. Huffman²¹, Sophie R. Wang^{22,23,24}, Cameron Palmer^{23,24}, Tõnu Esko¹⁰, Krista Fischer¹⁰, Jing Hua Zhao³, Ayşe Demirkan²⁵, Aaron Isaacs²⁵, Mary F. Feitosa²⁶, Jian'an Luan³, Nancy L. Heard-Costa²⁷, Charles White²⁷, Anne U. Jackson²⁸, Michael Preuss^{29,30}, Andreas Ziegler³⁰, Joel Eriksson³¹, Zoltán Kutalik^{19,20}, Francesca Frau³², Ilja M. Nolte³³, Jana V. Van Vliet-Ostaptchouk^{34,35}, Jouke-Jan Hottenga³⁶, Kevin B. Jacobs³⁷, Niek Verweij³⁸, Anuj Goel^{11,39}, Carolina Medina-Gomez^{40,41,42}, Karol Estrada^{40,41,42}, Jennifer Lynn Bragg-Gresham⁴³, Serena Sanna⁴⁴, Carlo Sidore^{43,45}, Jonathan Tyrer⁴⁶, Alexander Teumer⁴⁷, Inga Prokopenko^{11,48}, Massimo Mangino⁴⁹, Cecilia M. Lindgren¹¹, Themistocles L. Assimes⁵⁰, Alan R. Shuldiner^{15,51}, Jennie Hu^{52,53,54}, John P. Beilby^{52,53}, Wendy L. McArdle⁵⁵, Per Hall⁵⁶, Talin Haritunians⁵⁷, Lina Zgaga^{58,59}, Ivana Kolcic⁶⁰, Ozren Polasek⁶⁰, Tatijana Zemunik⁶⁰, Ben A. Oostra²⁵, M. Juhani Junttila⁶¹, Henrik Grönberg⁵⁶, Stefan Schreiber⁶², Annette Peters^{63,64}, Andrew A. Hicks⁶⁵, Jonathan Stephens^{66,67}, Nicola S. Foad^{66,67}, Jaana Laitinen⁶⁸, Anneli Pouta^{69,70}, Marika Kaakinen⁷¹, Goncke Willemssen³⁶, Jacqueline M. Vink³⁶, Sarah H. Wild⁵⁸, Gerjan Navis⁷², Folkert W. Asselbergs⁷³, Georg Homuth⁴⁷, Ulrich John⁷⁴, Carlos Iribarren⁷⁵, Tamara Harris⁷⁶, Lenore Launer⁷⁶, Vilmundur Gudnason^{13,14}, Jeffrey R. O'Connell¹⁵, Eric Boerwinkle⁷⁷, Gemma Cadby⁷⁸, Lyle J. Palmer⁷⁸, Alan L. James^{79,80}, Arthur W. Musk^{79,81}, Erik Ingelsson⁵⁶, Bruce M. Psaty^{82,83}, Jacques S. Beckmann^{19,84}, Gerard Waeber⁸⁵, Peter Vollenweider⁸⁵, Caroline Hayward²¹, Alan F. Wright²¹, Igor Rudan^{58,60}, Leif C. Groop⁸⁶, Andres Metspalu¹⁰, Kay Tee Khaw⁸⁷, Cornelia M. van Duijn²⁵, Ingrid B. Borecki^{26,88}, Michael A. Province^{26,88}, Nicholas J. Wareham³, Jean-Claude Tardif^{89,90}, Heikki V. Huikuri⁶¹, L. Adrienne Cupples^{27,91}, Larry D. Atwood²⁷, Caroline S. Fox⁹¹, Michael Boehnke²⁸, Francis S. Collins⁹², Karen L. Mohlke⁹³, Jeanette Erdmann^{29,94}, Heribert Schunkert^{29,94}, Christian Hengstenberg⁹⁵, Klaus Stark⁹⁵, Mattias Lorentzon³¹, Claes Ohlsson³¹, Daniele Cusi³², Jan A. Staessen^{96,97}, Melanie M. Van der Klauw^{34,35}, Peter P. Pramstaller^{98,99,100}, Sekar Kathiresan^{91,101,102,103,104}, Jennifer D. Jolley^{66,67}, Samuli Ripatti^{105,106,107}, Marjo-Riitta Jarvelin^{69,71,108}, Eco J. C. de Geus³⁶, Dorret I. Boomsma³⁶, Brenda Penninx¹⁰⁹, James F. Wilson⁵⁸, Harry Campbell⁵⁸, Stephen J. Chanock¹¹⁰, Pim van

©2012 Macmillan Publishers Limited. All rights reserved

Correspondence and requests for materials should be addressed to P.M.V. (peter.visscher@uq.edu.au).

Supplementary Information is available in the online version of the paper.

Author Contributions P.M.V., M.E.G. and J.Y. conceived and designed the study. J.Y. and P.M.V. derived the analytical theory. J.Y. performed the meta-analyses and simulations. J.Y. and P.M.V. wrote the first draft of the manuscript. J.Y., D.I.C., J.H.Z. and R.J.F.L. performed further statistical verification analyses. D.P.S., W.G.H., R.J.F.L., S.I.B. and H. Snieder contributed important additional concepts and critically reviewed the manuscript before submission. S.E.M., P.A.F.M., A.C.H., N.G.M., D.R.N. and G.W.M. contributed the individual-level genotype and phenotype data of the QIMR cohort. T.M.F., J.N.H. and R.J.F.L. liaised with the GIANT consortium for this project. The cohort-specific contributions of all other authors are provided in the Supplementary Information.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper.

der Harst³⁸, Anders Hamsten^{111,112}, Hugh Watkins^{11,39}, Albert Hofman^{41,42}, Jacqueline C. Witterman^{41,42}, M. Carola Zillikens⁴⁰, André G. Uitterlinden^{40,41,42}, Fernando Rivadeneira^{40,41,42}, M. Carola Zillikens⁴⁰, Lambertus A. Kiemeny¹¹³, Sita H. Vermeulen¹¹³, Goncalo R. Abecasis⁴³, David Schlessinger¹¹⁴, Sabine Schipf¹¹⁵, Michael Stumvoll^{116,117}, Anke Tönjes^{116,117}, Tim D. Spector⁴⁹, Kari E. North¹¹⁸, Guillaume Lettre^{89,90}, Mark I. McCarthy^{11,48,119}, Sonja I. Berndt¹¹⁰, Andrew C. Heath¹²⁰, Pamela A. F. Madden¹²⁰, Dale R. Nyholt², Grant W. Montgomery², Nicholas G. Martin², Barbara McKnight¹²¹, David P. Strachan¹⁷, William G. Hill¹²², Harold Snieder^{33,35}, Paul M. Ridker^{7,8}, Unnur Thorsteinsdottir^{9,123}, Kari Stefansson^{9,123}, Timothy M. Frayling¹²⁴, Joel N. Hirschhorn^{22,23,24}, Michael E. Goddard^{125,126}, and Peter M. Visscher^{1,2,127}

¹University of Queensland Diamantina Institute, The University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia ²Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4006, Australia ³MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge CB2 0QQ, UK ⁴Mount Sinai School of Medicine, New York, New York 10029, USA ⁵Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA ⁶Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, USA ⁷Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, Massachusetts 02215, USA ⁸Harvard Medical School, Boston, Massachusetts 02215, USA ⁹deCODE genetics, IS-101 Reykjavik, Iceland ¹⁰Estonian Genome Center, University of Tartu, Tartu 50410, Estonia ¹¹Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK ¹²Hudson Alpha Institute for Biotechnology, Huntsville, Alabama 35806, USA ¹³Icelandic Heart Association, IS-201 Kopavogur, Iceland ¹⁴University of Iceland, IS-101 Reykjavik, Iceland ¹⁵Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA ¹⁶Department of Epidemiology, The University of North Carolina, Chapel Hill, North Carolina 27514, USA ¹⁷Division of Population Health Sciences & Education, St George's, University of London, London SW17 0RE, UK ¹⁸Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA ¹⁹Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland ²⁰Swiss Institute of Bioinformatics, 1005 Lausanne, Switzerland ²¹MRC HGU at the MRC IGMM at the University of Edinburgh, Edinburgh EH8 9AG, UK ²²Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA ²³Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston, Massachusetts 02115, USA ²⁴Metabolism Initiative and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA ²⁵Department of Epidemiology, Subdivision Genetic Epidemiology, Erasmus MC, Rotterdam, The Netherlands ²⁶Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA ²⁷Boston University, Boston, Massachusetts 02118, USA ²⁸Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA ²⁹Universität zu Lübeck, Medizinische Klinik II, Ratzeburger Allee 160, 23538 Lübeck, Germany ³⁰Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, 23562 Lübeck, Germany ³¹Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden ³²Department of Health Sciences, University of Milano, 20133 Milano, Italy ³³Unit of Genetic Epidemiology & Bioinformatics, Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands ³⁴Department of Endocrinology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands ³⁵LifeLines Cohort Study, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands ³⁶Department of Biological Psychology, VU University, 1081 BT Amsterdam, The Netherlands ³⁷Core Genotyping Facility, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702, USA ³⁸Department of Cardiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen,

The Netherlands ³⁹Cardiovascular Medicine, University of Oxford, Oxford OX3 7BN, UK
⁴⁰Department of Internal Medicine, Erasmus MC, Rotterdam 3015GE, The Netherlands
⁴¹Department of Epidemiology, Erasmus MC, Rotterdam 3015GE, The Netherlands
⁴²Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), 2300 RC Leiden, The Netherlands ⁴³Biostatistics - Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA ⁴⁴Istituto di Ricerca Genetica e Biomedica, CNR, Monserrato 09042, Italy ⁴⁵Dipartimento di Scienze Biomediche, Università di Sassari, 07100 SS, Italy ⁴⁶Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK ⁴⁷Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17487 Greifswald, Germany ⁴⁸Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7BN, UK ⁴⁹Department of Twin Research and Genetic Epidemiology, King's College London, Lambeth Palace Road, London SE1 7EH, UK
⁵⁰Department of Medicine, Stanford University School of Medicine, Stanford 94305, California, USA ⁵¹Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, Maryland 21201, USA ⁵²Pathology and Laboratory Medicine, University of Western Australia, Nedlands Western Australia 6009, Australia ⁵³Molecular Genetics, PathWest Laboratory Medicine WA, University of Western Australia, Nedlands Western Australia 6009, Australia ⁵⁴School of Population Health, University of Western Australia, Nedlands Western Australia 6009, Australia ⁵⁵School of Social and Community Medicine, University of Bristol, Bristol BS8 2BN, UK ⁵⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden ⁵⁷Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA ⁵⁸Centre for Population Health Sciences, The University of Edinburgh Medical School, Edinburgh EH16 4TJ, UK ⁵⁹Andrija Stampar School of Public Health, Medical School University of Zagreb, Zagreb, Croatia ⁶⁰Faculty of Medicine, University of Split, Soltanska 2, 21000 Split, Croatia ⁶¹Institute of Clinical Medicine, Department Of Internal Medicine, University of Oulu, 90014 Oulu, Finland ⁶²Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, 24098 Kiel, Germany ⁶³Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany ⁶⁴Munich Heart Alliance, 80802 Munich, Germany ⁶⁵Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), 39100 Bolzano, Italy ⁶⁶Department of Haematology, University of Cambridge, Cambridge CB2 0PT, UK ⁶⁷NHS Blood and Transplant, Cambridge, Cambridge CB2 0PT, UK ⁶⁸Finnish Institute of Occupational Health, 90220 Oulu, Finland ⁶⁹National Institute for Health and Welfare, 90101 Oulu, Finland ⁷⁰Department of Clinical Sciences/Obstetrics and Gynecology, University of Oulu, 90014 Oulu, Finland ⁷¹Institute of Health Sciences, Biocenter Oulu, University of Oulu, 90014 Oulu, Finland ⁷²Department of Internal Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands ⁷³Department of Cardiology, Division Heart & Lungs, University medical Center Utrecht, 3508 GA Utrecht, The Netherlands ⁷⁴Institute of Epidemiology and Social Medicine, University Medicine Greifswald, 17475 Greifswald, Germany ⁷⁵Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA ⁷⁶National Institutes on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA ⁷⁷Human Genetics Center and Division of Epidemiology, The University of Texas Health Science Centers, Houston, Texas 77030, USA ⁷⁸Genetic Epidemiology and Biostatistics Platform, Ontario Institute for Cancer Research, Toronto, Ontario M5G 1L7, Canada ⁷⁹Medicine and Pharmacology, University of Western Australia, Nedlands Western Australia 6009, Australia ⁸⁰Pulmonary Physiology, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands Western Australia 6009, Australia ⁸¹Respiratory Medicine, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands Western Australia 6009, Australia ⁸²Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington 98101, USA ⁸³Group Health Research Institute, Group Health Cooperative, Seattle, Washington 98101, USA ⁸⁴Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV)

University Hospital, 1011 Lausanne, Switzerland ⁸⁵Department of Internal Medicine, University Hospital, 1011 Lausanne, Switzerland ⁸⁶Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden ⁸⁷Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK ⁸⁸Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri 63110, USA ⁸⁹Département de Médecine, Université de Montréal, Montréal, Québec H4J 1C5, Canada ⁹⁰Montreal Heart Institute, Montréal, Québec H1T 1C8, Canada ⁹¹Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University, Framingham, Massachusetts 01702, USA ⁹²National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA ⁹³Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599-7264, USA ⁹⁴Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Universität zu Lübeck, 23562 Lübeck, Germany ⁹⁵Klinik und Poliklinik für Innere Medizin II, 93053 Regensburg, Germany ⁹⁶Department of Cardiovascular Diseases, University of Leuven, 3000 Leuven, Belgium ⁹⁷Department of Epidemiology, Maastricht University, 6200 MD Maastricht, The Netherlands ⁹⁸Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), 39100 Bolzano, Italy ⁹⁹Department of Neurology, General Central Hospital, 39100 Bolzano, Italy ¹⁰⁰Department of Neurology, University of Lübeck, 23562 Lübeck, Germany ¹⁰¹Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA ¹⁰²Center for Human Genetics Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ¹⁰³Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ¹⁰⁴Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA ¹⁰⁵Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland ¹⁰⁶Public Health Genomics Unit, National Institute for Health and Welfare, 00271 Helsinki, Finland ¹⁰⁷Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK ¹⁰⁸Department of Epidemiology and Biostatistics, MRC-HPA Center for Environment and Health, Imperial College London, London W2 1PG, UK ¹⁰⁹Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands ¹¹⁰Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA ¹¹¹Karolinska Institutet, 171 77 Stockholm, Sweden ¹¹²Atherosclerosis Research Unit, Department of Medicine, Solna, 171 76 Stockholm, Sweden ¹¹³Epidemiology, Biostatistics & HTA, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands ¹¹⁴National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA ¹¹⁵Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany ¹¹⁶Department of Medicine, University of Leipzig, 04103 Leipzig, Germany ¹¹⁷IFB Adiposity Diseases, University of Leipzig, 04103 Leipzig, Germany ¹¹⁸Department of Epidemiology and Carolina Center for Genome Sciences, The University of North Carolina, Chapel Hill, North Carolina 27514, USA ¹¹⁹Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Old Road Headington, Oxford OX3 7LJ, UK ¹²⁰Department of Psychiatry, Washington University St Louis, Missouri 63110, USA ¹²¹Department of Biostatistics, University of Washington, Seattle, Washington 98115, USA ¹²²Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3JT, UK ¹²³Faculty of Medicine, University of Iceland, IS-101 Reykjavik, Iceland ¹²⁴Genetics of Complex Traits, Institute of Biomedical and Clinical Science, Peninsula Medical School, University of Exeter, Exeter EX1 2LU, UK ¹²⁵Department of Food and Agricultural Systems, University of Melbourne, Victoria 3010, Australia ¹²⁶Biosciences Research Division, Department of Primary Industries, Bundoorra, Victoria 3083, Australia ¹²⁷Queensland Brain Institute, The University of Queensland, Brisbane, Queensland 4072, Australia

Abstract

There is evidence across several species for genetic control of phenotypic variation of complex traits^{1–4}, such that the variance among phenotypes is genotype dependent. Understanding genetic control of variability is important in evolutionary biology, agricultural selection programmes and human medicine, yet for complex traits, no individual genetic variants associated with variance, as opposed to the mean, have been identified. Here we perform a meta-analysis of genome-wide association studies of phenotypic variation using 170,000 samples on height and body mass index (BMI) in human populations. We report evidence that the single nucleotide polymorphism (SNP) rs7202116 at the *FTO* gene locus, which is known to be associated with obesity (as measured by mean BMI for each rs7202116 genotype)^{5–7}, is also associated with phenotypic variability. We show that the results are not due to scale effects or other artefacts, and find no other experiment-wide significant evidence for effects on variability, either at loci other than *FTO* for BMI or at any locus for height. The difference in variance for BMI among individuals with opposite homozygous genotypes at the *FTO* locus is approximately 7%, corresponding to a difference of 0.5 kilograms in the standard deviation of weight. Our results indicate that genetic variants can be discovered that are associated with variability, and that between-person variability in obesity can partly be explained by the genotype at the *FTO* locus. The results are consistent with reported *FTO* by environment interactions for BMI⁸, possibly mediated by DNA methylation^{9,10}. Our BMI results for other SNPs and our height results for all SNPs suggest that most genetic variants, including those that influence mean height or mean BMI, are not associated with phenotypic variance, or that their effects on variability are too small to detect even with samples sizes greater than 100,000.

Genetic studies of complex traits usually focus on quantifying and dissecting phenotypic variation within populations, by contrasting mean differences in phenotypes between genotypes. For example, in association studies the difference between the average phenotype (P) of each genotype is tested. In addition, the phenotypic variance among individuals of the same genotype (G) can vary across genotypes, so that phenotypic variance conditional on genotype, $\text{var}(P|G)$, is not constant. Phenotypic variance given a particular genotype does not need to be due to sensitivity to external environmental factors but can, for example, be caused by developmental fluctuation of the internal micro-environment in a genotype-dependent manner¹. For example, genetic control of stochastic variation in development or in homeostatic control^{1,4}. The difference between genotypes can also depend on external factors, for example, on the environment in which they are reared, in which case there is a genotype by environment ($G \times E$) interaction. In species in which the same genotype can be measured across defined environments, such as in plant or animal populations, the difference in mean phenotype for each genotype can be quantified experimentally, and is known as the reaction norm of the genotype^{11,12}. However, any environment is likely to be heterogeneous, so that the environment experienced by each individual differs, although these differences are not formally recognized by the experimenter. In this situation, if a $G \times E$ interaction exists it may manifest as differences in environmental sensitivity so that genotypes differ in phenotypic variance. Therefore, even if the environments, internal or external, are not directly measured, evidence for genetic control of variation can be quantified through an analysis of variability.

There is empirical evidence for genetic control of phenotypic variation in several species¹, including *Drosophila*¹³, snails¹⁴, maize¹⁵ and chickens³, and specific quantitative trait loci with an effect on variance have been reported for yeast² and *Arabidopsis*⁴. Many theories and methods to identify genetic loci responsible for phenotypic variability have been proposed^{1,16–18}. In humans, there have been reports that variability of serum cholesterol and triglyceride levels within monozygotic twin pairs depends on their genotype at the MN blood group system¹⁹. In clinical practice, knowledge of phenotypic variability as a function of genotype may be important when the phenotypes are risk factors for disease or treatment

response, in particular when there are no mean differences between genotypes in the population¹⁹.

Detection of genetic variation in environmental or phenotypic variance requires large sample sizes because relative to their expected values, the variance has a larger sampling error than the mean^{16,20}. We performed a meta-analysis of genome-wide association studies (GWAS) of phenotypic variation for height and BMI in human populations on approximately 170,000 samples comprising 133,154 in a discovery set and 36,727 for *in silico* replication, and report a single locus with a genome-wide significant effect on variability in BMI. Height and BMI were chosen because genetic effects on variability in height and size traits have been reported in other species, and because very large samples of genotyped and phenotyped individuals are available through existing research consortia.

We performed a discovery meta-analysis of 38 studies consisting of 133,154 individuals (60% females) of recent European descent to identify SNPs that are associated with the variability of height or BMI. In each study, ~2.44 million genotyped and imputed autosomal SNPs were included in the analysis after applying quality-control filters. We adjusted height and BMI phenotypes for possible covariates such as age, sex and case-control status, and standardized them to *z* scores by an inverse-normal transformation. We then regressed the squared *z* scores (z^2), which are a measure of variance²⁰, on the genotype indicator variable of each SNP to test for association of the SNP with trait variability. The association statistics were corrected by the genomic control method²¹ in individual studies and then combined by an inverse-variance meta-analysis across all of the studies (see Methods). We selected 42 SNPs at 6 loci for height and 51 SNPs at 7 loci for BMI with $P < 5 \times 10^{-6}$ for *in silico* replication (Supplementary Fig. 1). We examined the top two SNPs at each of the 6 loci for height and 7 loci for BMI in a further sample of 36,727 individuals (54% females) of European ancestry from 13 studies (Methods). For BMI, only rs7202116 at the *FTO* locus (Fig. 1) and rs7151545 at the *RCOR1* locus (Supplementary Fig. 2) were replicated at genome-wide significance level, with $P = 2.9 \times 10^{-4}$ and $P = 3.6 \times 10^{-3}$ in the validation set and $P = 2.4 \times 10^{-10}$ and $P = 4.1 \times 10^{-8}$ in the combined set, respectively (Table 1). None of the height SNPs was replicated (Table 1). We show by an approximate conditional analysis using summary statistics from the discovery meta-analysis and estimated linkage disequilibrium structure from the Atherosclerosis Risk In Communities (ARIC) cohort that there is no secondary associated SNP in the *FTO* region when conditioning on rs7202116 (Supplementary Fig. 3). The estimate of the effect associated with rs7202116 on BMI z^2 was slightly larger in men (0.041, standard error (SE) = 0.009) than in women (0.033, SE = 0.007) in the combined set but the difference was not significant ($P = 0.670$). The *RCOR1* SNP only just passed the genome-wide significance level (5×10^{-8}), however, it did not reach the experiment-wise significance level (2.5×10^{-8}) considering that two independent traits were tested. There were several case-control studies included in the meta-analysis that were ascertained for diseases that may be correlated with BMI. We performed a further meta-analysis in the combined set excluding these case-control studies, and the *FTO* SNP rs7202116 remained genome-wide significant with $P = 2.8 \times 10^{-11}$ but the *RCOR1* SNP did not with $P = 3.6 \times 10^{-5}$ (Supplementary Table 1). We therefore focus on the *FTO* locus in the main text and provide the results for the *RCOR1* locus in the Supplementary Information.

On the scale on which BMI is measured, the predicted perallele effect of the G allele (the other allele is A) of rs7202116 on the mean difference is 0.37 kg m⁻² in men and 0.43 kg m⁻² in women²², and the effect on the variance difference is 0.79 kg² m⁻⁴ in men and 1.09 kg² m⁻⁴ in women, reflecting the larger standard deviation of BMI in women compared with men (Supplementary Table 2). Assuming an additive model, the mean difference between the GG and AA genotypes is 0.74 kg m⁻² in men and 0.86 kg m⁻² in women, with a

variance difference between the two genotypes of $1.58 \text{ kg}^2 \text{ m}^{-4}$ in men and $2.18 \text{ kg}^2 \text{ m}^{-4}$ in women, which is 7.2% of the phenotypic variance of BMI in both men and women. To provide an illustration of the effect of rs7202116 on BMI variance, we did an approximate calculation of its effect on the variance of weight. If we take the mean height of 1.78 m for men and 1.65 m for women, the difference in the variance of weight between the two genotype groups is roughly 16 kg^2 in both men and women (Supplementary Table 2). For example, if the standard deviation (SD) of weight is 15 kg for men, the predicted SD of weight in the two homozygous genotype classes is 14.73 and 15.27 kg, respectively.

The effect of a SNP on variance could be owing to our use of the χ^2 value as a measure of variance or to a general relationship between mean and variance of BMI^{1,23}. Below we present evidence that excludes these two explanations.

If an SNP has an effect on the mean, the test statistic for association of the SNP with χ^2 will be inflated, and the non-centrality parameter (NCP_{v0}) of the χ^2 test under the null hypothesis of no effect on variance is: $np(1-p)(1-2p)2(a+(1-2p)d)^4$, in which n is the sample size, p is the frequency of the coded allele, and a and d are the additive and dominance effects, respectively, on the mean difference (Supplementary Note). We show by analysis and simulation results based on an additive and dominance genetic model that such inflation is inversely proportional to the minor allele frequency (MAF) of the SNP; that is, SNPs with a lower MAF will tend to have higher test statistics under the null hypothesis (Supplementary Fig. 4). However, when we plotted the observed test statistics of the confirmed 180 height loci²⁴ and 32 BMI loci²² that have the largest reported effects on the mean, we did not observe such a trend (Supplementary Fig. 5). We calculated the NCP_{v0} of the known height and BMI loci given the effects on the mean from the published papers^{22,24}, and the NCP_{v0} values of all these known loci were smaller than 1 (results not shown). The observed genomic inflation factor in the discovery meta-analysis was 1.039 for height and 1.033 for BMI (Supplementary Fig. 6). This small inflation could be due to many SNPs affecting the mean and therefore having a tiny effect on χ^2 (Supplementary Fig. 7), or many SNPs that have an effect on the variance that is too small to be significant even with our large sample size. Across common SNPs in the genome, variants at the *FTO* locus have the largest effect size on BMI²². The G allele of the *FTO* SNP rs7202116 has a population frequency of ~0.4 and an additive effect on the mean BMI of ~0.1 z-score units^{5,22}. If our significant result at the *FTO* locus is due only to an allelic effect on mean BMI, we would expect an allelic effect on variability of ~0.002 (predicted from the equation in the Supplementary Note), which is very small compared with the observed effect of 0.036. For some traits, the variance changes in a predictable manner as the mean changes. In this case, a scale transformation, such as a logarithmic transformation, can remove effects on the variance when they are simply due to an effect on the mean¹. We were interested in effects of SNP on variability that would remain after a scale transformation, and therefore sought to exclude scale effects that could explain our observed association. We performed further analyses in three data sets each with approximately 20,000 individuals with individual-level genotype and phenotype data available to verify the effects of rs7202116 at the *FTO* locus on BMI variance (Methods and Table 2). We used several tests, including Bartlett's test statistic, to test for the difference in variance between the three genotypes. The Bartlett's test *P* value was <0.05 in each of the three data sets, regardless of whether or not the BMI phenotypes were adjusted for the mean difference, logarithm transformed or inverse-normal transformed (Table 2). In the combined analysis of the three data sets totalling 60,624 individuals, the effect of rs7202116 on the BMI χ^2 score after adjusting for the mean difference was 0.030 ($P = 1.2 \times 10^{-4}$) for inverse-normal transformed BMI, 0.065 (2.3×10^{-12}) for logarithm-transformed BMI, and 0.097 (8.9×10^{-16}) for BMI without scale transformation (Table 2). The decrease of the effect of rs7202116 on BMI χ^2 owing to the adjustment of the mean difference was ~0.003, in line with that of ~0.002 as predicted from

the theory above. Similar conclusions as above can be drawn from the further analyses for rs7151545 at the *RCOR1* locus (Supplementary Table 3). We plotted the test statistics and estimates for the effects on the variability in our discovery meta-analysis against those for the effects on the mean from the published GIANT meta-analyses for height²⁴ and BMI²², and did not find any apparent correlations except for a few outlying SNPs at the *FTO* locus (Supplementary Fig. 7). These results together suggest that the observed effect of the *FTO* SNP on variability is neither a consequence of the effect on the mean nor due to the choice of scale, and that our inverse-normal transformation is likely to be overly conservative. Results from reported quantile regression of untransformed BMI on a multiple SNP predictor of BMI and on *FTO*²⁵ are consistent with our results but are also consistent with scale effects due to the skewed distribution of untransformed BMI. We have shown in this study that the effect of *FTO* on variability is not due to a scale effect and, concordantly, a quantile regression of both transformed and untransformed BMI *z*-scores on the SNPs at the *FTO* and *RCOR1* loci on BMI on 17,974 individuals shows a relationship between effect size and the quantile of the distribution (Supplementary Fig. 8). By contrast, the use of untransformed BMI induces widespread correlation between estimated SNP effects on the mean and on variance (Supplementary Fig. 9).

We have reported a meta-analysis of GWAS of squared normalized residuals for two quantitative traits in human populations, and provide empirical evidence that the *FTO* and *RCOR1* loci influence phenotypic variance of obesity. Conversely, we did not observe any significant SNPs for height or any significant SNPs other than those at the *FTO* and *RCOR1* loci for BMI to be genome-wide significantly associated with phenotypic variance (Table 1), even for those loci known to have effects on the mean (Supplementary Fig. 5), which indicates that SNP effects on variance are uncommon for height and BMI, and those previously identified SNP effects on the mean, although very small, are robust to environmental perturbation. We provide evidence that the association between the *FTO* locus and BMI variability is not due to artefacts such as scale or ascertainment. We also discuss that it is implausible that the observed effect of the *FTO* SNP on variance is due to its strong linkage disequilibrium ($D' = 1$) with a causal variant that has a large effect on the mean (Supplementary Note). The *FTO* SNPs that are associated with variance are also associated with mean differences in BMI. Interestingly, this phenomenon seems to be restricted to the *FTO* gene and to obesity, because we did not observe such effects for height or for BMI at loci other than *FTO*. One possible explanation of the observation is a differential response to physical activity²⁶, because interactions between *FTO* genotypes and physical activity have been reported for the same SNPs as we report in this study: the G allele that is associated with an increase in mean BMI has a smaller effect in the group of people with a high level of physical activity than in the absence of physical activity^{8,27,28}. There may be other unknown lifestyle factors, including diet, that also interact with the *FTO* genotype and result in the observed effect on variability.

We do not provide a mechanism of how alleles at *FTO* influence variability (how *FTO* alleles affect the mean is also not known). However, the fact that the allele that increases obesity also increases variability suggests a breakdown of homeostatic control. Data on mice lacking the *Fto* gene suggest that the observed effects on mean obesity in humans may be due to upregulation or dysregulation of *FTO* expression, resulting in an increased susceptibility to obesity²⁹. If both upregulation and impairment of *FTO* expression have a role then this could provide a mechanism of the observed effect on variability. The *FTO* protein affects demethylation of nuclear RNA *in vitro*²⁹, but whether the efficiency of this process depends on the *FTO* genotype or how this may be related to the observed effects on BMI is not clear. Notably, a recent study reported that rs7202116 allele G, which is present on the obesity-susceptibility haplotype at the *FTO* locus, creates a CpG site along with other variants in perfect linkage disequilibrium with it⁹, and therefore risk alleles have increased

DNA methylation. In addition, it was reported that a CpG site in the first intron of *FTO* showed significant hypomethylation in type 2 diabetes cases relative to controls³⁰, and that the risk variant seems to have an effect on methylation status at other genes¹⁰. DNA methylation can be affected by environmental influences, including dietary and lifestyle factors, and may affect gene expression. For example, physical exercise may increase gene expression at the *FTO* locus, but less so in GG individuals compared with AA individuals because their alleles are more methylated. This therefore suggests a possible mechanism for the observed effects on both the mean and variability. However, more research is needed to determine the molecular effect and mechanism of *FTO* on both the levels and variability of obesity.

Overall, our findings are consistent with a low heritability of phenotypic variability¹ and no common genetic variants that account for a large proportion of variation in environmental or phenotypic variability. They also indicate an absence of widespread genotype-by-environment interaction effects, at least for height and obesity in humans and with interaction effects large enough to be detected in our study in which specific environmental factors were not identified. Nevertheless, the demonstration that individual genetic loci with effects on variability can be identified with sufficiently large sample sizes facilitates further study to understand the function and evolution of the genetic control of variation.

METHODS

Fifty-one studies were included in the meta-analysis. All individuals were of recent European descent. In each of the participating studies, genotyped SNPs that passed standard quality-control processes (missingness, Hardy–Weinberg equilibrium test and MAF) were used to impute the ungenotyped SNPs to the HapMap II CEU reference panel³¹. We excluded SNPs with imputation quality score <0.4 for IMPUTE³² and <0.3 otherwise^{33,34}. A summary of sample size, genotyping platform, quality-control filters and the imputation tool of all the participating studies is provided in Supplementary Table 4. We further excluded SNPs with MAF < 0.01 in each study or in the meta-analysis, and retained about 2.68 million autosomal SNPs in the analysis.

In each study, height and BMI phenotypes were adjusted for age and standardized to z score by an inverse-normal transformation. The analysis protocol supplied to all cohorts is given as a Supplementary Note. The descriptive statistics of phenotypes of each study are shown in Supplementary Table 5. The association analyses of phenotypic variability were performed on a single-SNP basis by the following additive genetic model: $y = \alpha + \beta x + e$, in which y is z^2 , α is the intercept, β is the additive SNP effect on z^2 , x is the allelic dosage coded as 0, 1 or 2 for the three genotype groups, and e is the residual. We stratified the analysis by gender group and/or case-control status where applicable. We selected 38 studies consisting of 133,154 individuals as the discovery set by the time when data were available. We collected summary-level association results of all the SNPs from these studies and adjusted the standard errors of all SNPs by the genomic control approach in each study²¹, that is, multiplying the standard errors of the estimates of β by the square root of the genomic inflation factor²¹. We then combined the effect of each SNP by an inverse-variance meta-analysis implemented in METAL³⁵. In a regression analysis, the squared standard error of the estimate of a SNP effect is: $\sigma^2/(2p(1-p)n)$, in which σ^2 is the residual variance, p is the frequency of the coded allele, and n is the sample size. This assumes Hardy–Weinberg equilibrium of genotype frequencies. If the effect size is small, σ^2 is approximately equal to the variance of y , which is 2. We checked the overall quality of each study by plotting the median of $1/SE$ across all SNPs against the reported sample size, and by plotting the median of $2p(1-p)nSE^2$ across all SNPs to see if it was close to 2 (Supplementary Fig. 10). We further estimated the effective sample size of each SNP by: $\tilde{n} =$

$2/(2p(1-p)SE^2)$, using the summary statistics of the whole discovery set, and excluded SNPs with $\tilde{n} < \text{mean}(\tilde{n}) - 2SD(\tilde{n})$ and retained ~2.44 million SNPs for both height and BMI. We collected data from a further 36,727 samples from 13 cohorts (Supplementary Tables 4 and 5), and validated the top SNPs at 6 associated loci for height and 7 for BMI ($P < 5 \times 10^{-6}$) in these extra samples.

We performed further analyses in three data sets with a total sample size of 60,624 with individual-level genotype and phenotype data to verify our findings. These three data sets include 22,888 individuals from the WGHS cohort, and 19,762 individuals from the EPIC cohorts, and a combined sample of 17,974 individuals from the ARIC, QIMR, NHS and HPFS cohorts, with 17,365 individuals from the EPIC cohort and 5,233 individuals from the NHS and HPFS cohorts not part of the meta-analysis. We used logarithm or inverse-normal transformation to remove a possible mean–variance relationship of BMI phenotypes, and adjusted the phenotype for the effect of the top SNP at the *FTO* or *RCOR1* locus on the mean of BMI. We performed permutation tests to assess the significance of the effect of *FTO* or *RCOR1* on BMI χ^2 with 10,000 permutations, and used the Bartlett's statistic to test for difference in variance of BMI between three genotypes for *FTO* or *RCOR*.

The plot of association results at the *FTO* locus in Fig. 1 was generated using LocusZoom³⁶ with the recombination rates and pairwise linkage disequilibrium r^2 values between SNPs estimated from the HapMap CEU panel³¹.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge funding from the Australian National Health and Medical Research Council (NHMRC grants 241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485, 613672, 613601 and 1011506), the US National Institutes of Health (grants AA07535, AA10248, AA014041, AA13320, AA13321, AA13326, DA12854 and GM057091) and the Australian Research Council (ARC grant DP1093502). A detailed list of acknowledgements by study is provided in the Supplementary Information. We apologize to authors whose work we could not cite owing to space restrictions.

References

1. Hill WG, Mulder HA. Genetic analysis of environmental variation. *Genet Res.* 2010; 92:381–395.
2. Ansel J, et al. Cell-to-cell stochastic variation in gene expression is a complex genetic trait. *PLoS Genet.* 2008; 4:e1000049. [PubMed: 18404214]
3. Wolc A, White IM, Avendano S, Hill WG. Genetic variability in residual variation of body weight and conformation scores in broiler chickens. *Poult Sci.* 2009; 88:1156–1161. [PubMed: 19439624]
4. Jimenez-Gomez JM, Corwin JA, Joseph B, Maloof JN, Kliebenstein DJ. Genomic analysis of QTLs and genes altering natural variation in stochastic noise. *PLoS Genet.* 2011; 7:e1002295. [PubMed: 21980300]
5. Frayling TM, et al. A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science.* 2007; 316:889–894. [PubMed: 17434869]
6. Dina C, et al. Variation in *FTO* contributes to childhood obesity and severe adult obesity. *Nature Genet.* 2007; 39:724–726. [PubMed: 17496892]
7. Scuteri A, et al. Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet.* 2007; 3:e115. [PubMed: 17658951]
8. Kilpeläinen TO, et al. Physical activity attenuates the influence of *FTO* variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med.* 2011; 8:e1001116. [PubMed: 22069379]

9. Bell CG, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the *FTO* type 2 diabetes and obesity susceptibility locus. *PLoS ONE*. 2010; 5:e14040. [PubMed: 21124985]
10. Almén MS, et al. Genome wide analysis reveals association of a *FTO* gene variant with epigenetic changes. *Genomics*. 2012; 99:132–137. [PubMed: 22234326]
11. Falconer DS. Selection in different environments: effects on environmental sensitivity (reaction norm) and on mean performance. *Genet Res*. 1990; 56:57–70.
12. Jinks JL, Connolly V. Selection for specific and general response to environmental differences. *Heredity*. 1973; 30:33–40.
13. Mackay TF, Lyman RF. *Drosophila* bristles and the nature of quantitative genetic variation. *Phil Trans R Soc Lond B*. 2005; 360:1513–1527. [PubMed: 16108138]
14. Ros M, et al. Evidence for genetic control of adult weight plasticity in the snail *Helix aspersa*. *Genetics*. 2004; 168:2089–2097. [PubMed: 15611178]
15. Ordas B, Malvar RA, Hill WG. Genetic variation and quantitative trait loci associated with developmental stability and the environmental correlation between traits in maize. *Genet Res*. 2008; 90:385–395.
16. Yang Y, Christensen OF, Sorensen D. Use of genomic models to study genetic control of environmental variance. *Genet Res*. 2011; 93:125–138.
17. Rönnegård L, Valdar W. Detecting major genetic loci controlling phenotypic variability in experimental crosses. *Genetics*. 2011; 188:435–447. [PubMed: 21467569]
18. Paré G, Cook NR, Ridker PM, Chasman DI. On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study. *PLoS Genet*. 2010; 6:e1000981. [PubMed: 20585554]
19. Martin NG, Rowell DM, Whitfield JB. Do the MN and Jk systems influence environmental variability in serum lipid levels? *Clin Genet*. 1983; 24:1–14. [PubMed: 6684513]
20. Visscher PM, Posthuma D. Statistical power to detect genetic loci affecting environmental sensitivity. *Behav Genet*. 2010; 40:728–733. [PubMed: 20428936]
21. Devlin B, Roeder K. Genomic control for association studies. *Biometrics*. 1999; 55:997–1004. [PubMed: 11315092]
22. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nature Genet*. 2010; 42:937–948. [PubMed: 20935630]
23. Struchalin MV, Dehghan A, Witteman JC, van Duijn C, Aulchenko YS. Variance heterogeneity analysis for detection of potentially interacting genetic loci: method and its limitations. *BMC Genet*. 2010; 11:92. [PubMed: 20942902]
24. Lango Allen H, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature*. 2010; 467:832–838. [PubMed: 20881960]
25. Williams PT. Quantile-specific penetrance of genes affecting lipoproteins, adiposity and height. *PLoS ONE*. 2012; 7:e28764. [PubMed: 22235250]
26. Silventoinen K, et al. Modification effects of physical activity and protein intake on heritability of body size and composition. *Am J Clin Nutr*. 2009; 90:1096–1103. [PubMed: 19710197]
27. Andreasen CH, et al. Low physical activity accentuates the effect of the *FTO* rs9939609 polymorphism on body fat accumulation. *Diabetes*. 2008; 57:95–101. [PubMed: 17942823]
28. Rampersaud E, et al. Physical activity and the association of common *FTO* gene variants with body mass index and obesity. *Arch Intern Med*. 2008; 168:1791–1797. [PubMed: 18779467]
29. Jia G, et al. N⁶-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated *FTO*. *Nature Chem Biol*. 2011; 7:885–887. [PubMed: 22002720]
30. Toperoff G, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. *Hum Mol Genet*. 2012; 21:371–383. [PubMed: 21994764]
31. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007; 449:851–861. [PubMed: 17943122]

32. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genom \times 10-wide association studies by imputation of genotypes. *Nature Genet.* 2007; 39:906–913. [PubMed: 17572673]
33. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol.* 2010; 34:816–834. [PubMed: 21058334]
34. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. *Bioinformatics.* 2007; 23:1294–1296. [PubMed: 17384015]
35. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]
36. Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010; 26:2336–2337. [PubMed: 20634204]




Figure 1. Test statistics ($-\log_{10}(P \text{ values})$) for association with BMI variability in the discovery meta-analysis of SNPs at the *FTO* locus against their physical location

The SNPs surrounding rs7202116 are colour-coded to reflect their linkage disequilibrium with rs7202116. The recombination rates are plotted in cyan to reflect local linkage disequilibrium structure. Genes, the position of exons and the direction of transcription from the University of California, Santa Cruz (UCSC) genome browser are noted. The P value for rs7202116 in the combined set is represented by a purple diamond, and that from the discovery set by a purple circle.

Table 1

Associations of the top 6 and 7 loci with variance of height and BMI, respectively

Chr.	SNP	bp	Nearest gene	CA	Discovery			In silico replication			Combined							
					Freq.	β	SE	P	n	Freq.	β	SE	P	n	β	SE	P	n
Height																		
1	rs6429820	14,210,915	PRDM2	G	0.196	-0.035	0.0071	1.0 × 10 ⁻⁶	129,200	0.209	-0.002	0.0131	8.9 × 10 ⁻¹	32,355	-0.027	0.0062	1.0 × 10 ⁻⁵	161,555
2	rs6429975	143,002,110	KYNU	T	0.180	-0.036	0.0074	1.0 × 10 ⁻⁶	129,196	0.177	-0.002	0.0137	8.9 × 10 ⁻¹	32,472	-0.028	0.0065	1.0 × 10 ⁻⁵	161,668
2	rs6748377	45,002,877	SIX3	T	0.175	-0.038	0.0075	4.0 × 10 ⁻⁷	129,183	0.185	-0.006	0.0138	6.7 × 10 ⁻¹	31,988	-0.031	0.0066	3.0 × 10 ⁻⁶	161,171
7	rs10486722	41,778,433	INHBA	C	0.339	0.029	0.0060	1.0 × 10 ⁻⁶	128,834	0.318	-0.005	0.0112	6.3 × 10 ⁻¹	32,416	0.021	0.0053	6.0 × 10 ⁻⁵	161,250
8	rs1026852	3,577,500	CSMD1	G	0.444	-0.029	0.0059	1.0 × 10 ⁻⁶	126,363	0.435	-0.004	0.0110	7.4 × 10 ⁻¹	31,837	-0.023	0.0052	7.0 × 10 ⁻⁶	158,200
14	rs12891343	34,453,301	BAZ1A	T	0.227	0.031	0.0068	5.0 × 10 ⁻⁶	128,725	0.225	0.012	0.0120	3.2 × 10 ⁻¹	36,150	0.027	0.0059	6.0 × 10 ⁻⁶	164,875
BMI																		
2	rs12328474	140,638,570	LRP1B	G	0.263	-0.038	0.0078	1.2 × 10 ⁻⁶	104,640	0.250	0.035	0.0152	2.0 × 10 ⁻²	32,403	-0.023	0.0069	1.1 × 10 ⁻³	137,043
2	rs10932241	208,685,200	CRYGD	C	0.407	0.028	0.0059	2.9 × 10 ⁻⁶	127,597	0.411	-0.006	0.0125	6.2 × 10 ⁻¹	28,641	0.022	0.0053	5.6 × 10 ⁻⁵	156,238
4	rs11942401	188,052,244	FAT	A	0.140	-0.043	0.0085	4.3 × 10 ⁻⁷	125,010	0.128	0.003	0.0187	8.5 × 10 ⁻¹	28,016	-0.035	0.0077	6.2 × 10 ⁻⁶	153,026
6	rs1418304	82,795,837	IBTK	G	0.496	-0.026	0.0057	3.3 × 10 ⁻⁶	127,611	0.493	0.004	0.0103	6.9 × 10 ⁻¹	36,721	-0.019	0.0050	1.2 × 10 ⁻⁴	164,332
14	rs12894649	102,232,512	RCOR1	C	0.057	0.061	0.0126	1.3 × 10 ⁻⁶	127,080	0.050	0.058	0.0248	1.9 × 10 ⁻²	32,298	0.060	0.0112	7.9 × 10 ⁻⁸	159,378
14	rs7151545	102,247,397	RCOR1	G	0.057	0.059	0.0126	2.4 × 10 ⁻⁶	127,080	0.053	0.083	0.0285	3.6 × 10 ⁻³	28,040	0.063	0.0115	4.1 × 10 ⁻⁸	155,120
16	rs7193144	52,368,187	FTO	C	0.403	0.030	0.0058	1.9 × 10 ⁻⁷	127,537	0.406	0.020	0.0115	8.0 × 10 ⁻²	32,449	0.028	0.0052	5.4 × 10 ⁻⁸	159,986
16	rs7202116	52,379,116	FTO	G	0.402	0.035	0.0067	2.0 × 10 ⁻⁷	95,966	0.417	0.039	0.0107	2.9 × 10 ⁻⁴	35,267	0.036	0.0057	2.4 × 10 ⁻¹⁰	131,233
18	rs620052	37,900,962	PIK3C3	G	0.378	0.033	0.0069	1.6 × 10 ⁻⁶	95,971	0.382	-0.010	0.0111	3.7 × 10 ⁻¹	34,668	0.021	0.0059	3.5 × 10 ⁻⁴	130,639

The squared z scores (z^2) were used to test for association of the top 6 and 7 SNPs with trait variability (height and BMI, respectively). The discovery set consists of 133,154 individuals, and data for *in silico* replication are from another 36,727 samples. At both the *FTO* and *RCOR1* loci, the second top SNPs (highlighted in bold) in the discovery set pass the single trait genome-wide significance level (5×10^{-8}) in the combined set. β , estimate of additive effect on z^2 ; bp, physical position; CA, coded allele; chr., chromosome; freq., frequency of the coded allele.

Table 2

Effects of the *FTO* SNP rs7202116 on BMI

	BMI		log(BMI)		BMI (inv. norm.)	
	Unadj.	Adj.	Unadj.	Adj.	Unadj.	Adj.
WGHS (<i>n</i> = 22,888)						
β	0.148	0.142	0.100	0.093	0.046	0.040
SE	0.021	0.020	0.015	0.015	0.013	0.013
<i>P</i>	4.5×10^{-13}	4.0×10^{-12}	5.5×10^{-11}	8.6×10^{-10}	6.8×10^{-4}	3.3×10^{-3}
Permutation <i>P</i>	$<1 \times 10^{-4}$	$<1 \times 10^{-4}$	$<1 \times 10^{-4}$	$<1 \times 10^{-4}$	9.0×10^{-4}	3.9×10^{-3}
Bartlett's <i>P</i>	1.1×10^{-24}	1.1×10^{-24}	2.0×10^{-11}	2.0×10^{-11}	6.5×10^{-3}	6.6×10^{-3}
Mean AA	-0.070	0.0	-0.069	0.0	-0.068	0.0
Mean AG	-0.001	0.0	-0.001	0.0	0.0	0.0
Mean GG	0.161	0.0	0.159	0.0	0.152	0.0
Variance AA	0.895	0.900	0.932	0.937	0.971	0.977
Variance AG	1.002	1.008	0.995	1.001	0.990	0.996
Variance GG	1.194	1.202	1.132	1.138	1.060	1.066
EPIC (<i>n</i> = 19,762)						
β	0.077	0.076	0.049	0.048	0.027	0.026
SE	0.021	0.021	0.017	0.017	0.014	0.014
<i>P</i>	1.7×10^{-4}	2.1×10^{-4}	3.2×10^{-3}	3.9×10^{-3}	6.1×10^{-2}	7.1×10^{-2}
Permutation <i>P</i>	$<1 \times 10^{-4}$	$<1 \times 10^{-4}$	4.9×10^{-3}	5.1×10^{-3}	6.4×10^{-2}	7.1×10^{-2}
Bartlett's <i>P</i>	7.6×10^{-7}	7.6×10^{-7}	3.0×10^{-3}	3.0×10^{-3}	1.2×10^{-1}	1.2×10^{-1}
Mean AA	-0.077	0.000	-0.076	0.000	-0.075	0.000
Mean AG	0.012	0.000	0.012	0.000	0.012	0.000
Mean GG	0.103	0.000	0.102	0.000	0.100	0.000
Variance AA	0.932	0.936	0.951	0.955	0.967	0.970
Variance AG	1.005	1.009	1.007	1.011	1.010	1.013
Variance GG	1.085	1.089	1.045	1.049	1.013	1.017
ARIC + QIMR + NHS + HPFS (<i>n</i> = 17,974)						
β	0.070	0.067	0.049	0.046	0.026	0.024
SE	0.022	0.022	0.017	0.017	0.015	0.015

	BMI		log(BMI)		BMI (inv. norm.)	
	Unadj.	Adj.	Unadj.	Adj.	Unadj.	Adj.
<i>P</i>	1.7×10^{-3}	2.8×10^{-3}	3.6×10^{-3}	6.1×10^{-3}	8.9×10^{-2}	1.2×10^{-1}
Permutation <i>P</i>	1.6×10^{-3}	2.6×10^{-3}	3.8×10^{-3}	7.1×10^{-3}	8.7×10^{-2}	1.2×10^{-1}
Bartlett's <i>P</i>	1.2×10^{-7}	1.2×10^{-7}	2.5×10^{-4}	2.5×10^{-4}	2.0×10^{-2}	2.0×10^{-2}
Mean AA	-0.067	0.0	-0.068	0.0	-0.069	0.0
Mean AG	0.006	0.0	0.008	0.0	0.010	0.0
Mean GG	0.122	0.0	0.118	0.0	0.113	0.0
Variance AA	0.968	0.973	0.978	0.983	0.994	0.998
Variance AG	0.968	0.972	0.974	0.978	0.975	0.979
Variance GG	1.131	1.136	1.093	1.097	1.059	1.064
Combined (<i>n</i> = 60,624)						
β	0.100	0.097	0.068	0.065	0.034	0.030
SE	0.012	0.012	0.009	0.009	0.008	0.008
<i>P</i>	8.9×10^{-17}	8.9×10^{-16}	1.4×10^{-13}	2.3×10^{-12}	2.4×10^{-5}	1.2×10^{-4}
Bartlett's <i>P</i>	1.3×10^{-32}	1.3×10^{-32}	8.5×10^{-15}	8.6×10^{-15}	4.4×10^{-4}	4.2×10^{-4}
Mean AA	-0.071	0.0	-0.071	0.0	-0.070	0.0
Mean AG	0.005	0.0	0.006	0.0	0.007	0.0
Mean GG	0.129	0.0	0.127	0.0	0.122	0.0
Variance AA	0.93	0.93	0.95	0.96	0.98	0.98
Variance AG	0.99	1.00	0.99	1.00	0.99	1.00
Variance GG	1.14	1.14	1.09	1.09	1.04	1.05

The effects of the *FTO* SNP rs7202116 on the variance for BMI and log(BMI) were tested in three subsets of data. The BMI phenotypes were corrected for age effect and standardized to z scores using the mean and standard deviation, or by an inverse-normal (inv. norm.) transformation in each gender group in each cohort. Phenotypes were adjusted (adj.) (or unadjusted (unadj.)) for mean difference in the three genotypes. For the EPIC cohort, 2,397 samples were in the meta-analysis, and 17,376 were not part of the meta-analysis. For the combined ARIC, QIMR, NHS and HPFS cohort, 12,741 samples were in the meta-analysis and 5,233 samples were not. β , the effect of the G allele on \mathcal{L}^2 ; Bartlett's *P*, *P*-value calculated from the Bartlett's test for variance difference in the three genotypes; EPIC, European Prospective Investigation into Cancer; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; permutation *P*, empirical *P*-value calculated from 10,000 permutations; QIMR, Queensland Institute of Medical Research; WGHs, Women's Genome Health Study.